Dynavax Technologies | DVAX - Pre Tax Profit



Dynavax Technologies reported $21.22M in Pre-Tax Profit for its fiscal quarter ending in June of 2025.


Pre Tax Profit Change Date
AbbVie USD 1.66B 3.15B Mar/2025
Adma Biologics USD 40.1M 5.39M Jun/2025
Amgen USD 1.57B 405M Jun/2025
AstraZeneca USD 3.13B 275M Jun/2025
Biogen USD 744M 432.8M Jun/2025
BioMarin Pharmaceutical USD 297.87M 59.78M Jun/2025
Bristol-Myers Squibb USD 1.77B 1.2B Jun/2025
Dynavax Technologies USD 21.22M 119.09M Jun/2025
Gilead Sciences USD 2.43B 780M Jun/2025
Glaxosmithkline USD 1.89B 230.76M Jun/2025
Merck USD 6.77B 864M Jun/2025
Neurocrine Biosciences USD 159.5M 144.8M Jun/2025
Novartis USD 4.53B 124M Jun/2025
Pfizer USD 3.04B 259M Jun/2025
Regeneron Pharmaceuticals USD 1.52B 613.7M Jun/2025
Roche Holding CHF 1.78B 2.33B Dec/2024
Sarepta Therapeutics USD 153.64M 537.16M Jun/2025
TG Therapeutics USD 30.92M 25.45M Jun/2025
Vertex Pharmaceuticals USD 1.28B 552.6M Jun/2025